Resource Summary Report

ES-2

RRID:CVCL_3509
Type: Cell Line

Proper Citation

(RRID:CVCL_3509)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3509

Proper Citation: (RRID:CVCL_3509)

Sex: Female

Defining Citation: PMID:1717140, PMID:9698466, PMID:11103784, PMID:12960427, PMID:16382445, PMID:17671176, PMID:18560578, PMID:18720132, PMID:20081105, PMID:20204287, PMID:20215515, PMID:22328975, PMID:22460905, PMID:22705003, PMID:22710073, PMID:23415752, PMID:23839242, PMID:24023729, PMID:25049276, PMID:25230021, PMID:25485619, PMID:25877200, PMID:25960936, PMID:26388441, PMID:26589293, PMID:27397505, PMID:28196595, PMID:28273451, PMID:30485824, PMID:30894373, PMID:30971826, PMID:31068700, PMID:35839778

Comments: Omics: Transcriptome analysis by serial analysis of gene expression (SAGE)., Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Secretome proteome analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: Genome sequenced., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep quantitative phosphoproteome analysis., Omics: Deep exome analysis., Omics: CRISPR phenotypic screen., Omics: Array-based CGH., Population: Caucasian., Part of: OCCP ovarian cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Probably misclassified. It is dubious that this cell line originates from an African American 47 year old patient diagnosed with an ovarian clear cell adenocarcinoma. Immunohistochemical and qPCR analysis as well as its mutational profile support an ovarian serous adenocarcinoma origin (PubMed=25049276; DOI=10.26502/ogr072). Furthermore its genome ancestry clearly shows a Caucasian/European decent (PubMed=30894373) which is confirmed by mtDNA haplotyping

(DOI=10.26502/ogr072)..

Category: Cancer cell line

Name: ES-2

Synonyms: ES2

Cross References: BTO:BTO_0004424, CLO:CLO_0002947, EFO:EFO_0002177, AddexBio:C0017006/4971, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1978, BCRC:60067, BCRJ:0080, BioGRID_ORCS_Cell_line:435, BioSample:SAMN02800400, BioSample:SAMN03472439, BioSample:SAMN10988319, cancercelllines:CVCL_3509, CCRID:1101HUM-PUMC000371, CCRID:3101HUMTCHu111, CCRID:4201HUM-CCTCC00322, CCTCC:GDC0322, Cell_Model_Passport:SIDM00861, CGH-DB:323-2, CLS:305038, Cosmic:844353, Cosmic:897429, Cosmic:1044235, Cosmic:1102814, Cosmic:1113277, Cosmic:1139225, Cosmic:1223312, Cosmic:1305327, Cosmic:1312191, Cosmic:1328071, Cosmic:1450145, Cosmic:1708382, Cosmic:1709256, Cosmic:1995396, Cosmic:2074240, Cosmic-CLP:1240128, DepMap:ACH-000906, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1240128, GEO:GSM95455, GEO:GSM274699, GEO:GSM313713, GEO:GSM383926, GEO:GSM416675, GEO:GSM659376, GEO:GSM784563, GEO:GSM887008, GEO:GSM888077, GEO:GSM1001491, GEO:GSM1176276, GEO:GSM1291140, GEO:GSM1340580, GEO:GSM1341129, GEO:GSM1669769, GEO:GSM2474975, IARC_TP53:28314, IGRhCellID:ES2, LiGeA:CCLE_094, LINCS_LDP:LCL-1806, PharmacoDB:ES2_337_2019, PRIDE:PXD000901, PRIDE:PXD030304, Progenetix:CVCL_3509, Ubigene:YC-C139, Wikidata:Q54832435

ID: CVCL_3509

Record Creation Time: 20220427T215835+0000

Record Last Update: 20250420T105959+0000

Ratings and Alerts

No rating or validation information has been found for ES-2.

No alerts have been found for ES-2.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 326 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Sasaki M, et al. (2025) Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. Cancer research communications, 5(1), 24.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Khetan R, et al. (2024) Unveiling G-protein coupled receptors as potential targets for ovarian cancer nanomedicines: from RNA sequencing data analysis to in vitro validation. Journal of ovarian research, 17(1), 156.

Zhang C, et al. (2024) Phosphorylation of FOXK2 at Thr13 and Ser30 by PDK2 sustains glycolysis through a positive feedback manner in ovarian cancer. Oncogene, 43(26), 1985.

Li J, et al. (2023) Whole-exome mutational landscape and molecular marker study in mucinous and clear cell ovarian cancer cell lines 3AO and ES2. BMC cancer, 23(1), 321.

Tang B, et al. (2023) Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer. Frontiers in oncology, 13, 1154073.

Buzza MS, et al. (2023) Intersection of Coagulation and Fibrinolysis by the Glycosylphosphatidylinositol (GPI)-Anchored Serine Protease Testisin. International journal of molecular sciences, 24(11).

Duda JM, et al. (2023) Differential histone deacetylase inhibitor-induced perturbations of the global proteome landscape in the setting of high-grade serous ovarian cancer. Proteomics, 23(3-4), e2100372.

Wu CH, et al. (2023) Zinc Finger Protein 90 Knockdown Promotes Cisplatin Sensitivity via Nrf2/HO-1 Pathway in Ovarian Cancer Cell. Cancers, 15(5).

Mo Y, et al. (2023) Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis. Molecular cancer, 22(1), 4.

Jiang W, et al. (2023) A NOTCH1 Mutation Found in a Newly Established Ovarian Cancer Cell Line (FDOVL) Promotes Lymph Node Metastasis in Ovarian Cancer. International journal of molecular sciences, 24(6).

Adamopoulos PG, et al. (2023) Hybrid-seq deciphers the complex transcriptional profile of the human BRCA1 DNA repair associated gene. RNA biology, 20(1), 281.

Zhang T, et al. (2023) Interleukin-6 and Hypoxia Synergistically Promote EMT-Mediated Invasion in Epithelial Ovarian Cancer via the IL-6/STAT3/HIF-1? Feedback Loop. Analytical

cellular pathology (Amsterdam), 2023, 8334881.

Shibuya Y, et al. (2023) SMAC Mimetics Synergistically Cooperate with HDAC Inhibitors Enhancing TNF-? Autocrine Signaling. Cancers, 15(4).

Li J, et al. (2023) Metabolic modulation of CtBP dimeric status impacts the repression of DNA damage repair genes and the platinum sensitivity of ovarian cancer. International journal of biological sciences, 19(7), 2081.

Rodriguez Torres S, et al. (2023) Epigallocatechin-3-Gallate Prevents the Acquisition of a Cancer Stem Cell Phenotype in Ovarian Cancer Tumorspheres through the Inhibition of Src/JAK/STAT3 Signaling. Biomedicines, 11(4).

Riillo C, et al. (2023) A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3?) for ovarian cancer. Journal of translational medicine, 21(1), 301.

Zhao G, et al. (2023) Neoprzewaquinone A Inhibits Breast Cancer Cell Migration and Promotes Smooth Muscle Relaxation by Targeting PIM1 to Block ROCK2/STAT3 Pathway. International journal of molecular sciences, 24(6).

Synowiec A, et al. (2023) Hypoxia, but Not Normoxia, Reduces Effects of Resveratrol on Cisplatin Treatment in A2780 Ovarian Cancer Cells: A Challenge for Resveratrol Use in Anticancer Adjuvant Cisplatin Therapy. International journal of molecular sciences, 24(6).

Wen J, et al. (2023) TUBA1A licenses APC/C-mediated mitotic progression to drive glioblastoma growth by inhibiting PLK3. FEBS letters, 597(24), 3072.